Critical reflection on landmark papers 2018

 General hepatology

Hepatology Arena
English
Science/Research
12 April 2019 16:00 - 18:00

Paper to be discussed: 

1) A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R.

N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519

2) Dysregulated Gut Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer

Singh V, Yeoh BS, Chassaing B, Xiao X, Saha P, Aguilera Olvera R, Lapek JD Jr, Zhang L, Wang WB, Hao S, Flythe MD, Gonzalez DJ, Cani PD, Conejo-Garcia JR, Xiong N, Kennett MJ, Joe B, Patterson AD, Gewirtz AT, Vijay-Kumar M.

Cell. 2018 Oct 18;175(3):679-694.e22. doi: 10.1016/j.cell.2018.09.004

3) Epidemiology and effects of bacterial infections in patients with cirhosis worldwide

Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, de Cassia Ribeiro Barea R, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Wong F, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bhamidimarri KR, Boyer TD, Maevskaya M, Fassio E, Kim HS, Hwang JS, Gines P, Gadano A, Sarin SK, Angeli P; International Club of Ascites Global Study Group.

Gastroenterology. 2018 Dec 12. pii:S0016-5085(18)35402-7

4) Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R,
Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri

M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators.

Lancet. 2018 Jun 16;391(10138):2417-2429.


Presentations

A placebo-controlled trial of bezafibrate in primary biliary cholangitis
12 April 2019 16:00 - 16:30

Lead author
Christophe Corpechot - France
12 April 2019 16:00 - 16:15

Challenger
Pietro Invernizzi - Italy
12 April 2019 16:15 - 16:25

Discussion
12 April 2019 16:25 - 16:30

Dysregulated gut microbial fermentation of soluble fiber induces cholestatic liver cancer
12 April 2019 16:30 - 17:00

Lead author
Matam Vijay-Kumar - United States
12 April 2019 16:30 - 16:45

Challenger
Mathias Heikenwälder - Germany
12 April 2019 16:45 - 16:55

Discussion
12 April 2019 16:55 - 17:00

Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide
12 April 2019 17:00 - 17:30

Lead author
Salvatore Piano - Italy
12 April 2019 17:00 - 17:15

Challenger
Rajiv Jalan - United Kingdom
12 April 2019 17:15 - 17:25

Discussion
12 April 2019 17:25 - 17:30

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
12 April 2019 17:30 - 18:00

Lead author
Paolo Caraceni - Italy
12 April 2019 17:30 - 17:45

Challenger
Aleksander Krag - Denmark
12 April 2019 17:45 - 17:55

Discussion
to be confirmed
12 April 2019 17:55 - 18:00